Trials / Completed
CompletedNCT06422767
Study to Evaluate the Effect of Bepirovirsen on Cardiac Conduction as Assessed by 12-lead Electrocardiogram in Healthy Volunteers
A Phase 1, Randomized, Double-Blinded, Placebo-Controlled, Parallel Group Study to Evaluate the Effect of Bepirovirsen on Cardiac Conduction as Assessed by 12-lead Electrocardiogram in Healthy Volunteers
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 46 (actual)
- Sponsor
- GlaxoSmithKline · Industry
- Sex
- All
- Age
- 18 Years – 55 Years
- Healthy volunteers
- Accepted
Summary
This study will evaluate the effect of a single dose of bepirovirsen on the QT interval corrected by Fridericia's formula (QTcF) as compared to placebo. The data generated will be used to model the relationship between bepirovirsen concentration and QTcF.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Bepirovirsen | Bepirovirsen will be administered. |
| DRUG | Placebo | Placebo will be administered. |
Timeline
- Start date
- 2024-07-18
- Primary completion
- 2025-04-28
- Completion
- 2025-04-28
- First posted
- 2024-05-21
- Last updated
- 2025-06-17
Locations
1 site across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT06422767. Inclusion in this directory is not an endorsement.